Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients

• DOI: 10.1111/all.15867
• Publication Date: 2023-08-26T05:34:56Z
• Authors: Dennis Thomas; Vanessa M. McDonald; Sean Stevens; Erin S. Harvey; Melissa Baraket; Philip Bardin; Jeffrey J. Bowden; Simon Bowler; Jimmy Chien; Li Ping Chung; Andrew Gillman; Mark Hew; Sandra Hodge; Alan James; Christine Jenkins; Constance H. Kate...; Gregory P. Katsou...; David Langton; Joy Lee; Guy Marks; Matthew Peters; Naghmeh Radhakrishna; Paul N. Reynolds; Janet Rimmer; Pathmanathan Siva...; John W. Upham; Peter Wark; Ian A. Yang; Peter G. Gibson
• Keywords: Omalizumab; Wheeze

Abstract Background Asthma remission has emerged as a potential treatment goal. This study evaluated the effectiveness of two biologics (mepolizumab/omalizumab) in achieving asthma remission. Methods observational included 453 severe patients (41% male; mean age ± SD 55.7 14.7 years) from real‐world drug registries: Australian Mepolizumab Registry and Xolair Registry. The composite outcome clinical was defined zero exacerbations oral corticosteroids during previous 6 months assessed at 12 5‐item Control Questionnaire (ACQ‐5) ≤1 months. We also plus optimization (post‐bronchodilator FEV1 ≥80%) or stabilization not greater than 5% decline baseline) lung function Sensitivity analyses explored various cut‐offs ACQ‐5/FEV1 scores. predictors were identified. Results 29.3% (73/249) AMR 22.8% (37/162) AXR cohort met criteria for When added, rates reduced to 25.2% 19.1%, respectively. identified that rate ranged between 18.1% 34.9% 10.6% 27.2% cohort. Better function, lower body mass index, mild disease absence comorbidities such obesity, depression osteoporosis predicted odds Conclusion Biologic with mepolizumab omalizumab asthma‐induced subgroup patients. Remission on may be an achievable target future studies should consider measure.